New Data Shows Gilead’s Remdesivir Improves Recovery for COVID-19 Patients

New data on Gilead Sciences’ remdesivir shows the antiviral reduced the risk of mortality for severe COVID-19 patients by 62 percent.

Gilead released the results of an analysis comparing patients treated in a phase 3 trial with a separate cohort of patients given standard of care. The analysis found that 74 percent of patients treated with remdesivir recovered by day 14 compared to 59 percent of those receiving standard of care alone.

Gilead said the new analysis supports the findings in the National Institutes of Health’s trial of remdesivir, which showed the drug shortened time to recovery by four days compared to placebo.